Press Release

CREATIVE DIAGNOSTICS ANNOUNCES NEW ANTIMICROBIAL SUSCEPTIBILITY TESTING SERVICES



Creative Diagnostics announced the launch of its new Antimicrobial Susceptibility Testing (AST) services.

FOR IMMEDIATE RELEASE

07/08/2023

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics announced the launch of its new Antimicrobial Susceptibility Testing (AST) services. These services are designed to help biotechnology and pharmaceutical researchers detect the sensitivity of test bacteria to antimicrobial drugs.

Antimicrobial susceptibility testing is a laboratory procedure that is primarily used to determine whether antimicrobial drugs have an inhibitory effect on pathogenic microorganisms in vitro. It can also be applied to clinically guide therapeutic drug selection and to understand changes in drug resistance of common pathogens in the region. Knowing the antibiotics to which bacteria are susceptible can shift the choice of antibiotics from empiric to targeted therapy.

Methods for testing drug susceptibility are based on exposing bacteria to antibiotics and observing their response ("phenotypic testing") or specific genetic testing ("genetic testing"). Currently, the major methods used in clinical microbiology laboratories for drug susceptibility testing include paper diffusion, dilution methods (including agar and broth dilution), antibiotic concentration gradient quantification, and automated instrumentation.

Creative Diagnostics now offers Antimicrobial Susceptibility Testing services to help researchers determine which specific antibiotics a particular bacteria or fungus is sensitive to. These new AST services provide guidance on antibiotic treatment options and can be integrated into GLP and GMP environments with full traceability. Creative Diagnostics' experts can provide rapid, objective interpretation of results, and its active/proactive product line development ensures optimal drug-microbe combinations.

Creative Diagnostics' AST services include Phenotypic and Genetic methods. The Phenotypic method test is based on bacterial exposure to antibiotics. The most commonly used test is the paper susceptibility test. A drug-sensitive paper is a filter paper containing a certain amount of antimicrobial drug. Then, using the paper diffusion method, the drug-sensitive paper is placed on the surface of agar inoculated with the test bacteria. The drug in the filter paper diffuses through the agar and the concentration of antimicrobial drug decreases logarithmically as the diffusion distance increases.

Genetic testing detects the presence of antibiotic resistance genes in the bacterial genome using methods such as polymerase chain reaction, DNA chip and loop-mediated isothermal amplification. These assays have the advantage of being direct and rapid compared to phenotypic methods. Meanwhile, Creative Diagnostics can handle a wide range of types, including Aminoglycoside, Beta-Lactam, Cephalosporin, Macrolide, Penicillin, Quinolone, and Tetracycline.

Creative Diagnostics combines infectious disease and analytical expertise to provide customers with the most robust portfolio of antiviral and antibacterial in vitro testing services. With the growing demand for new antiviral and antibacterial compounds to treat infectious diseases, Creative Diagnostics can also help clients test compounds in vitro to determine their potential efficacy in in vivo models.

For more information about Creative Diagnostics and its new Antimicrobial Susceptibility Testing services, please visit https://antiviral.creative-diagnostics.com/antimicrobial-susceptibility-testing.html.

About Creative Diagnostics

Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.

Tags:
Antimicrobial Susceptibility Tes  |  Creative Diagnostics  |  

---

Organisation Profile:
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. Our goal is to be a trusted source for all your assay development and manufacturing needs.






Press release contact details for Creative Diagnostics

NameCreative Diagnostics
Tel
Fax
Email
Websitehttps://www.creative-diagnostics.com/
OrganisationCreative Diagnostics
Address
Town
County0
Postcode11967




Other press releases from Creative Diagnostics

Creative Diagnostics Launches HPV L1 Antibodies for Neutralization and Vaccine Development
Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers
Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research
Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection
Creative Diagnostics Introduces Virus Yield Reduction Assay Service
Creative Diagnostics Introduces New Low Endotoxin Antibodies for Researchers
Creative Diagnostics Announces Calprotectin Reagents for Inflammatory Disease Research
Creative Diagnostics Introduces Viral Replicon Assay Service to Support Virology Research
Creative Diagnostics Announces the Launch of Radial Immunodiffusion Testing Service
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases
Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research
Creative Diagnostics Launches Antimicrobial Synergy Testing Services
Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications
Creative Diagnostics Launches Checkerboard Assay Services
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research
Creative Diagnostics Launches Minimum Inhibitory Concentration Testing Services
Creative Diagnostics Launches Carbamazepine Test Reagents
Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications
Creative Diagnostics Announces New Test Reagents for Dapsone
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing Read more: https://www.digitaljournal.com/pr/news/getnews/creative-diagnostics-announces-new-mbc-assay-for-antibacterial-testing#ixzz8KcL65cji
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing
Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues
Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness
Creative Diagnostics Launches New P53 and TP53 Antibodies for Cancer Research
Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety
Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens
Creative Diagnostics Announces New AAV Reagent Solutions for Gene Therapy
Citrinin Test Reagents for Food Safety
Creative Diagnostics Announces Novel Agar Gel Precipitin Tests for Viral Antigen Detection
Creative Diagnostics Introduces Cutting-Edge Anti-AAV Antibody ELISA Kits for Gene Therapy Research
Creative Diagnostics Announces the Launch of Its Highly Sensitive Kanamycin ELISA Kit for Precise Antibiotic Detection
Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development
Creative Diagnostics Announces Comprehensive Vomitoxin Test Reagents for Food Safety Applications

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.